Autolus Therapeutics Presents Prelim. Data From Ongoing Phase 1 CARLYSLE Trial In Patients With Severse Refractory Systemic Lupus Erythematosus

Benzinga · 1d ago
  • Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cells
  • All patients show deep B-cell depletion after infusion, suggesting an immune reset
  • Nine patients were evaluable for safety, no ICANS or high-grade CRS were observed